| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| 1 | 08-12-2025 | 06-30-2025 | 10-Q | |
| 2 | 05-13-2025 | 03-31-2025 | 10-Q | |
| 3 | 03-27-2025 | 12-31-2024 | 10-K | |
| 4 | 11-12-2024 | 09-30-2024 | 10-Q |
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
The SPDR S&P Biotech ETF (ARCA:XBI) is up more than 40% over the past six months and is on the verge of breaking out. Here...
https://www.sec.gov/Archives/edgar/data/2023658/000119312525230307/d54249ds3.htm
HC Wainwright & Co. analyst Robert Burns maintains Bicara Therapeutics (NASDAQ:BCAX) with a Buy and lowers the price tar...
Piper Sandler analyst Kelsey Goodwin initiates coverage on Bicara Therapeutics (NASDAQ:BCAX) with a Overweight rating and an...
Bicara Therapeutics (NASDAQ:BCAX) reported quarterly losses of $(0.50) per share which beat the analyst consensus estimate of $...
Bicara Therapeutics Inc. (NASDAQ: BCAX) shares are trading lower Friday following the release of updated interim data.
Wells Fargo analyst Eva Fortea Verdejo upgrades Bicara Therapeutics (NASDAQ:BCAX) from Underweight to Equal-Weight and maint...
